[go: up one dir, main page]

AR122182A2 - Procesos para la preparación de compuestos intermediarios de un inhibidor de pde4 y dichos compuestos intermediarios - Google Patents

Procesos para la preparación de compuestos intermediarios de un inhibidor de pde4 y dichos compuestos intermediarios

Info

Publication number
AR122182A2
AR122182A2 ARP210101430A ARP210101430A AR122182A2 AR 122182 A2 AR122182 A2 AR 122182A2 AR P210101430 A ARP210101430 A AR P210101430A AR P210101430 A ARP210101430 A AR P210101430A AR 122182 A2 AR122182 A2 AR 122182A2
Authority
AR
Argentina
Prior art keywords
intermediate compounds
preparation
processes
pde4 inhibitor
compounds
Prior art date
Application number
ARP210101430A
Other languages
English (en)
Inventor
Alessandro Falchi
Emilio Lutero
Emanuele Ferrari
Fausto Pivetti
Rocco Bussolati
Edoardo Mariani
Orsola Vecchi
Erhard Bappert
Caterina Ventrici
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49385193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR122182(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of AR122182A2 publication Critical patent/AR122182A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Proceso para la preparación de compuestos de fórmula (1) donde X es -NHSO₂Me, que comprende la reducción de los correspondientes derivados donde X es -NO₂ a los derivados amino y su posterior reacción con un haluro de metansulfonilo; procesos relacionados; y dichos compuestos intermediarios. Reivindicación 6: Compuestos intermediarios caracterizados porque tienen la fórmula (1), donde X se selecciona de -NHSO₂Me y -NO₂, y Z se selecciona de -OH, cloro, bromo, alcoxi (C₁-C₆) lineal o ramificado, ariloxi, arilalcoxi, alquilcarboniloxi (C₁-C₆), arilcarboniloxi y arilalquilcarboniloxi (C₁-C₆).
ARP210101430A 2013-10-22 2021-05-27 Procesos para la preparación de compuestos intermediarios de un inhibidor de pde4 y dichos compuestos intermediarios AR122182A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13189784 2013-10-22

Publications (1)

Publication Number Publication Date
AR122182A2 true AR122182A2 (es) 2022-08-24

Family

ID=49385193

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP140103938A AR098128A1 (es) 2013-10-22 2014-10-20 Proceso para la preparación de un inhibidor de pde4
ARP200100438A AR118124A2 (es) 2013-10-22 2020-02-17 Proceso para la preparación de un inhibidor de pde4
ARP210101430A AR122182A2 (es) 2013-10-22 2021-05-27 Procesos para la preparación de compuestos intermediarios de un inhibidor de pde4 y dichos compuestos intermediarios
ARP210101431A AR122183A2 (es) 2013-10-22 2021-05-27 Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP140103938A AR098128A1 (es) 2013-10-22 2014-10-20 Proceso para la preparación de un inhibidor de pde4
ARP200100438A AR118124A2 (es) 2013-10-22 2020-02-17 Proceso para la preparación de un inhibidor de pde4

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210101431A AR122183A2 (es) 2013-10-22 2021-05-27 Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato

Country Status (29)

Country Link
US (7) US9434691B2 (es)
EP (5) EP3798209A1 (es)
JP (5) JP6458957B2 (es)
KR (3) KR102287598B1 (es)
CN (5) CN114621139B (es)
AR (4) AR098128A1 (es)
AU (1) AU2014339136C1 (es)
BR (1) BR112016008161B1 (es)
CA (3) CA3115570C (es)
CY (1) CY1123811T1 (es)
DK (3) DK3293176T3 (es)
ES (3) ES2980505T3 (es)
FI (1) FI3587400T3 (es)
HR (3) HRP20192152T1 (es)
HU (3) HUE046637T2 (es)
IL (4) IL285532B2 (es)
LT (2) LT3293176T (es)
MX (4) MX389002B (es)
MY (1) MY182559A (es)
PH (3) PH12020500162B1 (es)
PL (3) PL3060551T3 (es)
PT (3) PT3587400T (es)
RS (2) RS61558B1 (es)
RU (1) RU2682660C9 (es)
SG (4) SG10201912852YA (es)
SI (3) SI3587400T1 (es)
TW (3) TWI720803B (es)
UA (2) UA121853C2 (es)
WO (1) WO2015059050A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171256A1 (es) 2010-08-03 2017-08-28 Chiesi Farm Spa Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
RS61558B1 (sr) 2013-10-22 2021-04-29 Chiesi Farm Spa Kristalni oblik pde4 inhibitora
US20190275022A1 (en) * 2016-07-20 2019-09-12 Allergan, Inc. Methods, compositions, and compounds for treatment of dermatological and ocular conditions
JP7361584B2 (ja) * 2018-12-19 2023-10-16 高砂香料工業株式会社 アミドの還元によるアミンの製造方法
JP6780763B2 (ja) 2018-12-25 2020-11-04 トヨタ自動車株式会社 内燃機関の制御装置
US11149615B2 (en) 2018-12-25 2021-10-19 Toyota Jidosha Kabushiki Kaisha Control device for internal combustion engine
CN111808029A (zh) * 2020-08-31 2020-10-23 兰晟生物医药(苏州)有限公司 一种pde4抑制剂氯比普兰的制备方法
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
CA3250500A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. CRYSTALLINE FORM OF A PHOSPHODIESTERASE 4 INHIBITOR
CN115304542B (zh) * 2022-07-18 2024-02-02 湖南华纳大药厂手性药物有限公司 一种3-羟基吡啶的合成工艺
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
GEAP202516740A (en) 2022-09-22 2025-05-27 Chiesi Farm Spa Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
CN119947705A (zh) 2022-09-22 2025-05-06 奇斯药制品公司 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器
IL319639A (en) 2022-09-22 2025-05-01 Chiesi Farm Spa Capsule inhaler for administration of a phosphodiesterase-4 inhibitor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
AU2001239442A1 (en) * 2000-03-30 2001-10-15 Chirotech Technology Limited Ruthenium-diphosphine complexes and their use as catalysts
EP1670742A1 (en) * 2003-09-12 2006-06-21 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
HUE029459T2 (en) 2004-04-19 2017-02-28 Krka Tovarna Zdravil D D Novo Mesto Methods for the Preparation of Polymorph Form I of Clopidogrel Hydrogen Sulphate
WO2005111025A1 (en) * 2004-04-29 2005-11-24 Aventis Pharmaceuticals Inc. 3-piperidinylisochroman-5-ols as dopamine agonists
KR20070079278A (ko) 2006-02-01 2007-08-06 삼성전자주식회사 수신자 제한 시스템을 이용하는 디지털 멀티미디어시스템에서 수신기의 채널 전환 시간 단축 장치 및 방법
EP2044023B1 (en) * 2006-07-14 2011-01-19 CHIESI FARMACEUTICI S.p.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
MY146022A (en) * 2006-12-22 2012-06-15 Leo Pharma As Substituted acetophenones useful as pde4 inhibitors
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US20100015430A1 (en) 2008-07-16 2010-01-21 Outlast Technologies, Inc. Heat Regulating Article With Moisture Enhanced Temperature Control
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CA2802584C (en) 2010-06-14 2018-08-21 Chiesi Farmaceutici S.P.A. Crystal form of glycopyrronium chloride
PE20171256A1 (es) * 2010-08-03 2017-08-28 Chiesi Farm Spa Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
CN106377503A (zh) * 2010-08-03 2017-02-08 奇斯药制品公司 包含磷酸二酯酶抑制剂的药物制剂
CA2817629C (en) 2010-11-23 2019-08-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
EP2760838B1 (en) * 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013087749A1 (en) * 2011-12-16 2013-06-20 Chiesi Farmaceutici S.P.A. Potentiation induced by pde4 inhibitors in the treatment of leukemia
ES2716142T3 (es) * 2012-12-05 2019-06-10 Chiesi Farm Spa Derivados del alcohol de 1-fenil-2-piridinil alquilo como inhibidores de la fosfodiesterasa
CN103304408B (zh) * 2013-06-05 2016-10-05 威海迪素制药有限公司 罗氟司特中间体3-环丙甲氧基-4-二氟甲氧基苯甲酸的制备
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
RS61558B1 (sr) * 2013-10-22 2021-04-29 Chiesi Farm Spa Kristalni oblik pde4 inhibitora
KR101591785B1 (ko) 2013-12-24 2016-02-04 주식회사 투게더 데이터 입력 장치, 이를 이용한 데이터 전송 시스템 및 방법
EP3732164A1 (en) * 2017-12-28 2020-11-04 Chiesi Farmaceutici S.p.A. Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis
CN118475343A (zh) * 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂

Also Published As

Publication number Publication date
CN110256338A (zh) 2019-09-20
CA3115587A1 (en) 2015-04-30
PH12020500162A1 (en) 2021-08-02
JP6458957B2 (ja) 2019-01-30
FI3587400T3 (fi) 2024-06-20
US20150111931A1 (en) 2015-04-23
SG10202112587RA (en) 2021-12-30
PL3060551T3 (pl) 2020-03-31
US9434691B2 (en) 2016-09-06
TW201904945A (zh) 2019-02-01
US20220348545A1 (en) 2022-11-03
BR112016008161A2 (es) 2017-08-01
IL285532A (en) 2021-09-30
IL285528A (en) 2021-09-30
MX2019014408A (es) 2020-01-27
EP3587400A3 (en) 2020-03-25
RS65452B1 (sr) 2024-05-31
MX389002B (es) 2025-03-20
US9890122B2 (en) 2018-02-13
EP3798209A1 (en) 2021-03-31
EP3587400A2 (en) 2020-01-01
TW202021952A (zh) 2020-06-16
IL245220A (en) 2017-06-29
AU2014339136B2 (en) 2018-05-31
US20240166605A1 (en) 2024-05-23
SG10201912852YA (en) 2020-02-27
TWI685486B (zh) 2020-02-21
KR102240865B1 (ko) 2021-04-16
IL245220A0 (en) 2016-06-30
CN114621139B (zh) 2025-06-20
SG10201903575UA (en) 2019-05-30
AR122183A2 (es) 2022-08-24
JP2021011494A (ja) 2021-02-04
CN120607463A (zh) 2025-09-09
PT3587400T (pt) 2024-06-05
PH12016500737B1 (en) 2022-03-23
BR112016008161B1 (pt) 2022-11-29
ES2759514T3 (es) 2020-05-11
IL252834B (en) 2021-09-30
MY182559A (en) 2021-01-25
HUE053112T2 (hu) 2021-06-28
US10323003B2 (en) 2019-06-18
MX2022000030A (es) 2022-07-19
PH12021550257A1 (en) 2023-01-23
JP2019038813A (ja) 2019-03-14
US20190345108A1 (en) 2019-11-14
CY1123811T1 (el) 2022-05-27
LT3293176T (lt) 2021-03-25
JP7345581B2 (ja) 2023-09-15
RU2682660C2 (ru) 2019-03-20
IL285532B2 (en) 2024-03-01
PH12020500162B1 (en) 2024-06-14
KR20160072127A (ko) 2016-06-22
ES2857629T3 (es) 2021-09-29
IL285528B2 (en) 2025-09-01
CN120136784A (zh) 2025-06-13
AU2014339136C1 (en) 2019-10-31
CA2928242C (en) 2022-03-15
PL3587400T3 (pl) 2024-07-01
DK3060551T3 (da) 2019-10-28
EP3060551A1 (en) 2016-08-31
RU2682660C9 (ru) 2019-06-21
US11981639B2 (en) 2024-05-14
ES2980505T3 (es) 2024-10-01
CA3115570A1 (en) 2015-04-30
KR102287598B1 (ko) 2021-08-11
HUE046637T2 (hu) 2020-03-30
KR102240865B9 (ko) 2021-12-13
JP2022068321A (ja) 2022-05-09
HRP20240783T1 (hr) 2024-09-27
EP3293176A1 (en) 2018-03-14
DK3293176T3 (da) 2021-02-15
MX370104B (es) 2019-12-02
EP3293176B1 (en) 2020-12-02
RU2016115246A (ru) 2017-11-27
US20160326117A1 (en) 2016-11-10
UA127453C2 (uk) 2023-08-30
HRP20192152T1 (hr) 2020-02-21
CN105658629B (zh) 2019-07-16
TWI651305B (zh) 2019-02-21
RU2016115246A3 (es) 2018-06-27
US10759761B2 (en) 2020-09-01
KR20210021416A (ko) 2021-02-25
TW201605804A (zh) 2016-02-16
SI3587400T1 (sl) 2024-05-31
SG11201603130TA (en) 2016-05-30
UA121853C2 (uk) 2020-08-10
AR098128A1 (es) 2016-05-04
CN114621139A (zh) 2022-06-14
JP7534346B2 (ja) 2024-08-14
AR118124A2 (es) 2021-09-22
EP3587400B1 (en) 2024-03-20
CN105658629A (zh) 2016-06-08
MX2022000036A (es) 2022-07-19
PL3293176T3 (pl) 2021-06-28
EP4059921A1 (en) 2022-09-21
KR20210021415A (ko) 2021-02-25
DK3587400T3 (da) 2024-04-02
RS61558B1 (sr) 2021-04-29
SI3293176T1 (sl) 2021-04-30
JP2022071008A (ja) 2022-05-13
HUE067681T2 (hu) 2024-11-28
WO2015059050A1 (en) 2015-04-30
US20180118686A1 (en) 2018-05-03
TWI720803B (zh) 2021-03-01
US20210040040A1 (en) 2021-02-11
IL252834A0 (en) 2017-08-31
KR102287596B1 (ko) 2021-08-11
CA3115570C (en) 2024-01-30
JP2017505752A (ja) 2017-02-23
CA2928242A1 (en) 2015-04-30
MX2016004834A (es) 2016-07-19
LT3587400T (lt) 2024-04-25
IL285532B1 (en) 2023-11-01
HK1223926A1 (zh) 2017-08-11
PT3293176T (pt) 2021-03-03
HRP20210336T1 (hr) 2021-04-16
US11352327B2 (en) 2022-06-07
SI3060551T1 (sl) 2019-11-29
IL285528B1 (en) 2025-05-01
CA3115587C (en) 2026-01-06
JP7051970B2 (ja) 2022-04-11
PT3060551T (pt) 2019-12-09
PH12016500737A1 (en) 2016-05-30
EP3060551B1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
AR122182A2 (es) Procesos para la preparación de compuestos intermediarios de un inhibidor de pde4 y dichos compuestos intermediarios
CU20180059A7 (es) Compuestos inhibidores de la quinasa de unión a tank
BR112017003568A2 (pt) composição detergente líquida para lavagem de roupas
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
CL2016001287A1 (es) Benzamidas sustituidas y procedimiento para su uso
BR112015029254A2 (pt) composição detergente de baixo ph compreendendo tensoativos não iônicos
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
MX2015011311A (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos del mismo como inhibidores de atotaxina.
BR112016006209A2 (pt) composição de polímero termoplástico
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
ECSP13012519A (es) Compuestos sustituidos de benzamida
DK3149105T3 (da) Anvendelse af syntetiske syresammensætninger som alternativer til konventionelle syrer i olie- og gasindustrien
BR112017001453A2 (pt) composição detergente para lavagem de roupas
EA201992510A1 (ru) Композиция с высоким содержанием глицерина, содержащая смеси алкилизетионата и алкилтаурата
BR112015009600A2 (pt) piridina-2-amidas úteis como agonistas cb2
CO6990738A2 (es) Agentes de reversion anticoagulante
DOP2014000098A (es) 2-tiopirimidinonas
AR103350A1 (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
BR112017003255A2 (pt) ?precursor para fazer um detergente, detergente e método para sua produção?
CL2013003093A1 (es) Composiciones que comprende cation de polihidroxioxoaluminio detectable por rmn; metodo de fabricacion de los mismos; y su uso.
UY35772A (es) Nuevos compuestos plaguicidas
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
MX381478B (es) Composicion dispersante liquida para yeso.